DoD Neurofibromatosis, Clinical Trial Award | W81XWH 22 NFRP CTA

Opportunity Information: Apply for W81XWH 22 NFRP CTA

The Department of Defense Neurofibromatosis Research Program (NFRP) Clinical Trial Award is a funding opportunity intended to speed up the launch and execution of clinical trials that could meaningfully improve the treatment or day-to-day management of neurofibromatosis (NF). The emphasis is on studies that can make a real difference for patients, whether by testing something new or by strengthening the evidence for approaches that are already emerging in the field. Importantly, this mechanism is specifically for clinical trials and the funded work must involve human subjects receiving an intervention under a prospective assignment design.

This award supports a wide range of trial types and stages, from early feasibility efforts to larger, more definitive studies. On the early end, applicants can propose proof-of-concept or exploratory trials such as pilot studies, first-in-human studies, or phase 0 work designed to show feasibility, identify signals of activity, refine endpoints, and inform the structure of later-phase trials. On the later end, the opportunity also allows for larger trials intended to determine efficacy in relevant NF patient populations. The program is flexible about what is being tested, as long as the project is structured as a clinical trial and is positioned to have a significant impact on NF care.

Interventions that may be evaluated under this award include promising new products and treatments such as pharmacologic agents (including drugs and biologics), medical devices, clinical guidance or care strategies, and newer approaches or technologies that could change how NF is treated or managed. The underlying goal is rapid implementation, meaning applicants should be ready to move into an active clinical testing phase rather than proposing preclinical or purely preparatory research. The announcement explicitly signals that investigators whose work is preclinical should pursue other NFRP funding announcements instead of this one.

The opportunity uses either a grant or a cooperative agreement as the funding instrument, under the Department of Defense (Department of the Army, U.S. Army Medical Research Acquisition Activity, USAMRAA). It is categorized as discretionary funding in the science and technology/research and development space and is associated with CFDA number 12.420. Eligibility is described as unrestricted, meaning it is broadly open to many entity types, subject to any additional eligibility clarifications included in the full announcement text.

The program also highlights compliance expectations around human subjects protections. It provides a specific Human Research Protections Office resource document for applicants to consult, reinforcing that proposals must be aligned with appropriate ethical, regulatory, and oversight requirements typical of interventional human subjects research. In practical terms, applicants should expect that the submission and review process will scrutinize the clinical trial design, readiness to enroll participants, appropriateness of outcomes, risk management, and human subjects protections, since the award is explicitly built to fund an actual clinical trial rather than exploratory lab work.

Key administrative details from the source listing include the funding opportunity title "DoD Neurofibromatosis, Clinical Trial Award" and the opportunity number W81XWH 22 NFRP CTA. The posting indicates an original closing date of July 21, 2022, and a creation date of April 11, 2022. The listing shows an expected number of awards as 1, and the award ceiling is displayed as 0 in the source data, which typically signals that the ceiling may be defined elsewhere in the full program announcement or handled through programmatic budgeting rather than a simple fixed cap in the listing.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Neurofibromatosis, Clinical Trial Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 11, 2022.
• Applicants must submit their applications by Jul 21, 2022. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 1 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 22 NFRP CTA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: